Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) COO Sells 3,416 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,416 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $22,067.36. Following the completion of the transaction, the chief operating officer directly owned 136,717 shares of the company’s stock, valued at $883,191.82. The trade was a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Alistair Milnes also recently made the following trade(s):

• On Friday, January 2nd, Alistair Milnes sold 3,244 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.80, for a total transaction of $22,059.20.

Bicycle Therapeutics Stock Down 0.6%

Shares of NASDAQ:BCYC traded down $0.04 during trading on Tuesday, reaching $6.57. The stock had a trading volume of 259,093 shares, compared to its average volume of 215,285. The stock has a market cap of $455.76 million, a P/E ratio of -1.81 and a beta of 1.52. The business has a fifty day moving average price of $6.97 and a 200-day moving average price of $7.42. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. The firm had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, equities analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its holdings in Bicycle Therapeutics by 454.1% in the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock worth $4,840,000 after acquiring an additional 572,439 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Bicycle Therapeutics by 64.7% in the third quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after purchasing an additional 451,135 shares during the period. Tybourne Capital Management HK Ltd. boosted its stake in shares of Bicycle Therapeutics by 72.4% in the second quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after purchasing an additional 417,400 shares during the period. Woodline Partners LP acquired a new stake in Bicycle Therapeutics during the 1st quarter valued at $3,088,000. Finally, Millennium Management LLC increased its stake in Bicycle Therapeutics by 156.5% during the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock worth $3,850,000 after buying an additional 276,671 shares during the period. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Truist Financial began coverage on shares of Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company. Finally, JMP Securities set a $12.00 price target on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.73.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.